AmerisourceBergen Corp (Holding Co) Stock News

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lin

Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances.

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.

HCA Healthcare's (HCA) third-quarter results are expected to reflect better emergency room visits and outpatient surgeries, partly offset by the continued incidence of labor costs.

AmerisourceBergen (ABC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

After a few years of stagnation, shares of AmerisourceBergen have come to life again. AmerisourceBergen is seeing solid growth, leverage is low, and opioid settlements have been announced.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2022 on Thursday, November 3, 2022,

Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into a strategic relationship with healthcare company AmerisourceBergen in preparation for the anticipated commercial launch in the United St

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

AmerisourceBergen (ABC) inks a deal to acquire PharmaLex to support its goal to become a strategic partner of choice for pharma customers for clinical and commercial enablement solutions.

AmerisourceBergen (ABC) inks a deal to acquire PharmaLex to support its goal to become a strategic partner of choice for pharma customers for clinical and commercial enablement solutions.

Life sciences research tool supplier Abcam said it will seek to delist from the AIM on London’s stock exchange following a “positive shareholder response”.

AmerisourceBergen Corp. ABC, -0.18% said Monday it has agreed to acquire PharmaLex Holding GmbH, a German company offering specialized services for the life sciences industry, or 1.28 billion euros ($